Analysts on Wall Street project that Catalyst Pharmaceutical (CPRX) will announce quarterly earnings of $0.42 per share in its forthcoming report, representing a decline of 40% year over year. Revenues are projected to reach $140.02 million, declining 1.3% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Catalyst metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to come in at $96.43 million. The estimate indicates a change of +16.9% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product revenue, Net- FYCOMPA' will reach $12.28 million. The estimate suggests a change of -67.9% year over year.
According to the collective judgment of analysts, 'Revenues- Product revenue, Net- AGAMREE' should come in at $31.30 million. The estimate indicates a year-over-year change of +48.5%.
The average prediction of analysts places 'Revenues- Product revenue,net' at $140.01 million. The estimate indicates a year-over-year change of -1.3%.
View all Key Company Metrics for Catalyst here>>>
Over the past month, Catalyst shares have recorded returns of +0.5% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #3 (Hold), CPRX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
